UPDATE: Deutsche Bank Raises PT to $95 on Gilead Sciences on Latest Data
Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $75 to $95.
Deutsche Bank said, "At the liver meeting today, Bristol ns5a and GILD nuke showed 100pct SVR with or without ribavirin, in patients that showed up for follow-up. So far 68/82 patients are at SVR12 timeframe and it was noted all 68 were undetectable. While Bristol and Abbott also have regimens with high cure rates, they require more pills (3 drug DAA) and likely will require ribavirin."
Gilead Sciences closed at $73.92 on Monday.
Latest Ratings for GILD
|Nov 2016||Stifel Nicolaus||Initiates Coverage On||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.